Literature DB >> 1341090

The Malaria Vaccine Epidemiology and Evaluation Project of Papua New Guinea: rationale and baseline studies.

M P Alpers1, F al-Yaman, H P Beck, K K Bhatia, J Hii, D J Lewis, R Paru, T A Smith.   

Abstract

The range of possible malaria vaccines, against different species of Plasmodium and various stages in the life cycle of the parasite in both human host and mosquito vector, is reviewed. The importance, in a malaria-endemic area, of protection by a malaria vaccine against disease rather than infection is emphasized, and the ways by which disease prevention may be achieved are discussed. Mechanisms of production and presentation of vaccines are considered, including the importance of appropriate and more effective adjuvants. The variety of immune responses to malaria is set out and linked to both human and plasmodial genetic factors. Host genetics may also modify susceptibility to malaria through mechanisms which are not immunological. There is a need for entomological studies of the Anopheles vectors, especially but not only in preparation for transmission-blocking vaccines. This overall complexity justifies a multidimensional approach to epidemiology and field-site preparation. An iterative procedure is proposed for initial field evaluation, through adult male volunteers to community studies in immune adults and then to semi-immune school children, before evaluation in the principal target population of nonimmune young children. The outcome variables for epidemiological evaluation are specified. After this brief review of malaria vaccines, the baseline studies being undertaken by the Malaria Vaccine Epidemiology and Evaluation Project of the Papua New Guinea Institute of Medical Research in the Wosera area of East Sepik Province are discussed in some detail, and their rationale linked to the range and complexity of the malaria vaccines that have been reviewed. These studies are described under the headings of their principal components of epidemiology, parasitology, immunology, genetics and entomology.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1341090

Source DB:  PubMed          Journal:  P N G Med J        ISSN: 0031-1480


  6 in total

1.  Sequence diversity and molecular evolution of the merozoite surface antigen 2 of Plasmodium falciparum.

Authors:  I Felger; V M Marshal; J C Reeder; J A Hunt; C S Mgone; H P Beck
Journal:  J Mol Evol       Date:  1997-08       Impact factor: 2.395

2.  Humoral and cell-mediated immunity to the Plasmodium falciparum ring-infected erythrocyte surface antigen in an adult population exposed to highly endemic malaria.

Authors:  H P Beck; I Felger; B Genton; N Alexander; F al-Yaman; R F Anders; M Alpers
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

3.  Research challenges and gaps in malaria knowledge in Papua New Guinea.

Authors:  James W Kazura; Peter M Siba; Inoni Betuela; Ivo Mueller
Journal:  Acta Trop       Date:  2011-08-27       Impact factor: 3.112

4.  Plasmodium vivax antigen discovery based on alpha-helical coiled coil protein motif.

Authors:  Nora Céspedes; Catherine Habel; Mary Lopez-Perez; Angélica Castellanos; Andrey V Kajava; Catherine Servis; Ingrid Felger; Remy Moret; Myriam Arévalo-Herrera; Giampietro Corradin; Sócrates Herrera
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

5.  Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif.

Authors:  Viviane Villard; George W Agak; Géraldine Frank; Ali Jafarshad; Catherine Servis; Issa Nébié; Sodiomon B Sirima; Ingrid Felger; Myriam Arevalo-Herrera; Socrates Herrera; Frederic Heitz; Volker Bäcker; Pierre Druilhe; Andrey V Kajava; Giampietro Corradin
Journal:  PLoS One       Date:  2007-07-25       Impact factor: 3.240

6.  Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea.

Authors:  Blaise Genton; Valérie D'Acremont; Lawrence Rare; Kay Baea; John C Reeder; Michael P Alpers; Ivo Müller
Journal:  PLoS Med       Date:  2008-06-17       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.